Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.82 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.82 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.82 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.82 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.82 |
| ▸ | RHOC | P08134 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | THRB | P10828 | 1/20 | 0.82 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.82 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.82 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.79 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.79 |
| ▸ | PDE6D | O43924 | 4/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7453854 | 1.00 | HMGCR (0.82) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL7449990 | 0.94 | HMGCR (0.79) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL14508069 | 0.93 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL9976581 | 0.93 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL8931058 | 0.93 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL5240504 | 0.93 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12553314 | 0.93 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12073622 | 0.92 | HMGCR (0.79) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL14508071 | 0.92 | HMGCR (0.78) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12072456 | 0.92 | HMGCR (0.78) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211664-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2022-07-07 | — | — | US | disclosed |
| US-9828594-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828594-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160355801-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION | 2016-12-08 | — | — | US | disclosed |
| US-20160355801-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION | 2016-12-08 | — | — | US | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150125928-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC | 2015-05-07 | — | — | US | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-20100009426-A1 | synthetic or recombinant polypeptide having a nitrilase activity; have increased activity and stability at increased pH and temperature | VERENIUM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009426-A1 | synthetic or recombinant polypeptide having a nitrilase activity; have increased activity and stability at increased pH and temperature | VERENIUM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-7608445-B1 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608445-B1 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008106662-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211664-A1 | LYMPH DIRECTING PRODRUGS | LTA, ABCB11, LYN | HMGCR 1833/4885SLCO1B1 139/4885ABCB11 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.